Clinical trial / 2010
A curcumin-phosphatidylcholine complex improved clinical endpoints and inflammatory markers in osteoarthritis patients over eight months.
An eight-month controlled study evaluated the efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, in 100 osteoarthritis patients. Significant improvements in both clinical endpoints (WOMAC score, Karnofsky Performance Scale Index, and treadmill walking performance) and biochemical endpoints (IL-1beta, IL-6, sCD40L, sVCAM-1, and ESR) were observed for Meriva compared to the control group. The authors reported excellent tolerability.
- Study type
- Controlled clinical trial
- Who was studied
- 100 osteoarthritis patients
- What was measured
- WOMAC score, Karnofsky Performance Scale Index, treadmill walking performance, and inflammatory markers
THE PAPER
Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients.
Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Altern Med Rev, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.